Clinical Trial Update: SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days) [Phase 2]

View source ↗

Summary

A Phase 2 trial (SNIFF 120) tested intranasal insulin for forgetfulness in people with Mild cognitive impairment and Alzheimer's disease; the study status is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• Nasal insulin (insulin)

Snippet

Sponsor: University of Washington | Conditions: Mild Cognitive Impairment, Alzheimer's Disease | Phase 2 | Status: COMPLETED